Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Scilex Holding Company before investing.

In this article, we go over a few key elements for understanding Scilex Holding Company’s stock price such as:

• Scilex Holding Company’s current stock price and volume
• Why Scilex Holding Company’s stock price changed recently
• Upgrades and downgrades for SCLX from analysts
• SCLX’s stock price momentum as measured by its relative strength

About Scilex Holding Company (SCLX)

Before we jump into Scilex Holding Company’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is based in Palo Alto, California.

Want to learn more about Scilex Holding Company’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Scilex Holding Company.

Scilex Holding Company’s Stock Price as of Market Close

As of January 21, 2026, 3:32 PM, CST, Scilex Holding Company’s stock price was $10.590.

Scilex Holding Company is down 2.75% from its previous closing price of $10.890.

During the last market session, Scilex Holding Company’s stock traded between $10.345 and $11.120. Currently, there are approximately 11.60 million shares outstanding for Scilex Holding Company.

Scilex Holding Company’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Scilex Holding Company Stock Price History

Scilex Holding Company’s (SCLX) price is currently down 13.2% so far this month.

During the month of January, Scilex Holding Company’s stock price has reached a high of $14.050 and a low of $10.345.

Over the last year, Scilex Holding Company has hit prices as high as $34.270 and as low as $3.600. Year to date, Scilex Holding Company’s stock is down 13.2%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Scilex Holding Company Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 20, 2026, there were 0 analysts who downgraded Scilex Holding Company’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Scilex Holding Company’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Scilex Holding Company’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Scilex Holding Company’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Scilex Holding Company (SCLX) by visiting AAII Stock Evaluator.

Relative Price Strength of Scilex Holding Company

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 20, 2026, Scilex Holding Company has a weighted four-quarter relative price strength of -1.80%, which translates to a Momentum Score of 43 and is considered to be Average.

Want to learn more about how Scilex Holding Company is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Scilex Holding Company Stock Price: Bottom Line

As of January 21, 2026, Scilex Holding Company’s stock price is $10.590, which is down 2.75% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Scilex Holding Company stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.